The Orthobiologics Market is anticipated to expand its boundaries at a CAGR of 3.0% during the forecast period. The market holds a share of USD 6.0 billion in 2023, while it is expected to cross a value of USD 8.1 billion by 2033.
The orthobiologics market outlook states that the increased healthcare budget is pushing the adoption of advanced healthcare equipment with advancing technology. Furthermore, bone-related disorders & injuries are propelling the growth of the orthobiologics market. The increase in the overall patient tally is likely to impact the market positively. The increased application of viscosupplements for delaying knee replacement and surgeries is also pushing healthcare facilities to adopt orthobiologics products.
Along with this, the long physical pain is also pushing end users to adopt technologies that prevent and delay painful surgeries. The rising amount of product introductions is likely to impact the sales of orthobiologics products. Increasing accidents in urban spaces are leading to higher bone disorders and fractures, leading to the adoption of orthobiologics in the healthcare systems.
The advanced integration systems with research and development extensions are creating exciting future opportunities for biological substances that are healing musculoskeletal injuries quickly. The products include bone allograftchevron, soft tissue allograftchevron, and cartilage allograftchevron. Though, orthopedic biologic products work as an optimum treatment solution for knee and shoulder injuries.
| Attributes | Details |
|---|---|
| Orthobiologics Market CAGR (2023 to 2033) | 3.0% |
| Orthobiologics Market Size (2023) | USD 6.0 billion |
| Orthobiologics Market Size (2033) | USD 8.1 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Short-term Growth: Growing research and development programs in bone and joints are expected to thrive in the market during the period. This also enhanced the company's engagement in orthobiologics and its product.
Mid-term Growth: Increasing geriatric population with age-related dysfunction to the bone-related system is expected to drive the market growth, as elderly people are more prone to fragility fractures and the incidents of fracture are more likely to increase by 10 to 15 times.
Long-term Growth: Growth is expected in the future for orthobiologics as their acceptance as an alternative treatment of orthopedic issues, and bone-related surgeries gain traction. Furthermore, advanced orthobiologics products are penetrating households with people suffering from long-term orthopedic pain. The restoring orthobiologics market is expected to flourish at a CAGR of 3% between 2023 and 2033.
The increasing geriatric population offers surplus opportunities for the manufacturers of orthobiologics. The crucial root of amputations is diseases related to aging as osteoarthritis, musculoskeletal diseases, spine deformity, etc.
Increased incidence of accidents owing to increasing urbanization is also a key factor expected to create numerous opportunities for orthobiologics manufacturers. Elevating surgical procedures also presents growth opportunities for the market.
The increased incidences of trauma cases, lifestyle-related diseases, and other chronic disorders have led to a rise in numerous orthopaedic surgeries at a global level. This growing trend is anticipated to increase the sales of orthobiologics products in the present and forthcoming years.
The emergence of online sales channels and government initiatives bot are contributing to the growth of the market. Manufacturers are focused on creating sales directly through their company’s website to target more customers without the interference of third-party distributors. This enables the manufacturers to eliminate the variation in product pricing owing to the involvement of third-party suppliers.
Principal Consultant
| Regions | Absolute Market Growth |
|---|---|
| United States | USD 749.0 million |
| United Kingdom | USD 73.3 million |
| China | USD 61.2 million |
| Japan | USD 179.5 million |
| India | USD 13.6 million |
The United States spends High Capital on Orthopedic Enhancements and Future Solutions.
| Region | Attributes |
|---|---|
| United States Market CAGR (2023 to 2033) | 3.2% |
| United States Market Absolute Doller Growth (USD million/billion) | USD 749.0 million |
The United States leads the orthobiologics market in terms of market share, as it is expected to hold a value of USD 2.8 billion by 2033. Increased healthcare budget, rising per capita income, and advancements in the field of orthopedics are expected to accelerate market growth.
The citizens are more likely to choose the alternative treatment than go through surgery. The United States spinal implants and orthobiologics portfolio showcases the positive result of the substitute products and how they help the end user in relieving pain. The region is expected to thrive at a CAGR of 3.2% through 2033.
Latest Innovative Products have Transformed the Future of the Global Orthobiologics Market
| Region | Attributes |
|---|---|
| United Kingdom Market CAGR (2023 to 2033) | 2.5% |
| United Kingdom Market Absolute Doller Growth (USD million/billion) | USD 73.3 million |
The United Kingdom increased its healthcare audits along with the soaring frequency of accidents and the geriatric population. These efforts are likely to help the industry boom. Furthermore, the advanced diagnosis and treatment procedures push the United Kingdom market with an expected value of USD 339.9 million by 2033.
The rising awareness of alternative orthopedic treatment fuels the demand for orthobiologics products. The nation is likely to expand at a CAGR of 2.5% through 2033.
| Region | Attributes |
|---|---|
| Indian Market CAGR (2023 to 2033) | 6.6% |
| Indian Market Absolute Doller Growth (USD million/billion) | USD 13.6 million |
India is constantly building their healthcare sector along with the adoption of advanced orthobiologic products. Furthermore, the integration of regenerative medicines of orthobiologics with platelet-rich plasma therapy is making India the leading market in terms of CAGR. The thriving Indian market is an outcome of the fusion and the belief system of patients that stick with regenerative medicine and alternative treatment. The market is expected to flourish at a CAGR of 6.6% between 2023 to 2033.
| Segment | Top Product Type |
|---|---|
| Top Sub-segment | Bone Graft Substitute |
| CAGR (2017 to 2022) | 2.9% |
| CAGR (2023 to 2033) | 3.5% |
| Segment | Top End User |
|---|---|
| Top Sub-segment | Hospitals |
| CAGR (2017 to 2022) | 8.5% |
| CAGR (2023 to 2033) | 9.1% |
The bone graft substitute segment in the product type category is expected to dominate the global market in the forecast period. This segment has been a lucrative one since 2012. During the 2012 to 2016 timeline, the bone graft substitute segment reflected high growth opportunities and led the global market.
This trend is observed in the current market scenario and is expected to continue over the period of assessment. In 2017, the bone graft substitute segment reached a value of USD 2,521.6 million, and according to the growth trend exhibited by this segment, it is estimated to reach a market valuation of above USD 3 billion by the end of 2027. During the forecast period from 2023 to 2033, it is poised to reflect a CAGR of 3.5%. However, the segment flourished at a CAGR of 2.9% between 2017 and 2022.
The bone graft substitute segment is further analyzed and divided into allograft, xenograft, synthetic, and bone morphogenetic protein sub-segments. This is the second leading segment in terms of market value. Allograft and synthetic sub-segments have a notable yet almost equal contribution to the revenue of the parent segment.
The allograft sub-segment reached a valuation of USD 937.5 million by 2022, leading other sub-segments. However, the synthetic subcategory is poised to grow at a relatively higher rate than allografts in the coming years.
Based on end users, the hospital segment thrives at a CAGR of 9.1% during the forecast period. This growth is attributed to the expansion of hospitals as governments focus more on infrastructure. The higher space and capacity to implement and use orthobiologic products also fuels their consumption of them in hospitals.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market players are focusing on creating advanced products that provide ease to patients. The research and development programs that deliver products to support the patient in their overall recovery process are another factor competitors focus on. This involves the integration of regenerative medicine, alternative therapies, and bone support products.
Latest Developments:
| Attribute | Details |
|---|---|
| Market Size Value in 2023 | USD 6 billion |
| Market Size Value in End of Forecast (2033) | USD 8.1 billion |
| Market Analysis | USD billion for Value |
| Key Region Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa (MEA); Others |
| Key Segments | By Product Type, By End User, By Region |
| Key Companies Profiled | Medtronic (Ireland); Zimmer Biomet; DePuy Synthes (Johnson & Johnson Services, Inc.); Stryker; Anika Therapeutics, Inc.; SeaSpine; Bioventus; RTI Surgical; MTF Biologics; Arthrex, Inc.; Smith & Nephew |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The market is valued at USD 6.0 billion in 2023.
Panasonic, Vishay, and Silicon Labs are top market players.
The pharmaceutical industry is the primary consumer of the orthobiologics market.
The market is estimated to reach USD 8.1 billion by 2033.
The market trend for orthobiologics is expected to record a CAGR of 3.0% by 2033.
1. Executive Summary | Orthobiologics Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product Type 5.1. Bone Growth Stimulators 5.1.1. Non-Invasive 5.1.2. Invasive 5.1.3. Ultrasound 5.2. Viscosupplements 5.2.1. One Injection 5.2.2. Three Injection 5.2.3. Five Injection 5.3. Bone Graft Substitute 5.3.1. Allografts 5.3.2. Synthetics 5.3.3. Xenografts 5.3.4. BMP 6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 6.1. Hospitals 6.2. Ambulatory Surgical Centers 6.3. Orthopedic Clinics 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific excluding Japan 7.5. Japan 7.6. Middle East and Africa 8. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 11. Asia Pacific excluding Japan Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 12. Japan Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 13. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Market Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. Medtronic plc 16.2. NuVasive, Inc. 16.3. Stryker Corporation 16.4. Zimmer Biomet Holdings 16.5. Orthofix International N.V. 16.6. Anika Therapeutics, Inc. 16.7. DePuy Synthes 16.8. Bioventus 16.9. Arthrex, Inc. 16.10. SeaSpine Holdings Corporation 16.11. Sanofi SA 16.12. Djo Global, Inc. 16.13. Seikagaku Corporation 16.14. RTI Surgical, Inc. 16.15. Heraeus Holding GmbH 16.16. Fidia Pharma USA Inc. 16.17. TRB Chemedica International SA 16.18. Allosource 16.19. Musculoskeletal Transplant Foundation, Inc. 16.20. Ito Co., Ltd. 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Orthobiologics Market
